Dianthus Therapeutics Statistics
Total Valuation
DNTH has a market cap or net worth of $566.98 million. The enterprise value is $236.84 million.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DNTH has 32.16 million shares outstanding. The number of shares has increased by 215.79% in one year.
| Current Share Class | 32.16M |
| Shares Outstanding | 32.16M |
| Shares Change (YoY) | +215.79% |
| Shares Change (QoQ) | +2.16% |
| Owned by Insiders (%) | 0.20% |
| Owned by Institutions (%) | 60.84% |
| Float | 10.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 95.82 |
| Forward PS | 162.52 |
| PB Ratio | 1.71 |
| P/TBV Ratio | 1.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 36.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.99, with a Debt / Equity ratio of 0.00.
| Current Ratio | 15.99 |
| Quick Ratio | 15.59 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -28.73% and return on invested capital (ROIC) is -20.83%.
| Return on Equity (ROE) | -28.73% |
| Return on Assets (ROA) | -20.04% |
| Return on Invested Capital (ROIC) | -20.83% |
| Return on Capital Employed (ROCE) | -35.34% |
| Revenue Per Employee | $83,641 |
| Profits Per Employee | -$1.29M |
| Employee Count | 78 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.58% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -25.58% |
| 50-Day Moving Average | 19.18 |
| 200-Day Moving Average | 22.61 |
| Relative Strength Index (RSI) | 45.27 |
| Average Volume (20 Days) | 292,020 |
Short Selling Information
The latest short interest is 6.69 million, so 20.79% of the outstanding shares have been sold short.
| Short Interest | 6.69M |
| Short Previous Month | 6.41M |
| Short % of Shares Out | 20.79% |
| Short % of Float | 60.85% |
| Short Ratio (days to cover) | 23.36 |
Income Statement
In the last 12 months, DNTH had revenue of $6.52 million and -$100.73 million in losses. Loss per share was -$2.81.
| Revenue | 6.52M |
| Gross Profit | 6.52M |
| Operating Income | -117.20M |
| Pretax Income | -56.68M |
| Net Income | -100.73M |
| EBITDA | -117.10M |
| EBIT | -117.20M |
| Loss Per Share | -$2.81 |
Full Income StatementBalance Sheet
The company has $263.23 million in cash and $1.40 million in debt, giving a net cash position of $330.14 million or $10.27 per share.
| Cash & Cash Equivalents | 263.23M |
| Total Debt | 1.40M |
| Net Cash | 330.14M |
| Net Cash Per Share | $10.27 |
| Equity (Book Value) | 328.61M |
| Book Value Per Share | 10.23 |
| Working Capital | 254.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$90.87 million and capital expenditures -$97,000, giving a free cash flow of -$90.97 million.
| Operating Cash Flow | -90.87M |
| Capital Expenditures | -97,000 |
| Free Cash Flow | -90.97M |
| FCF Per Share | -$2.83 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -1,796.40% |
| Pretax Margin | -1,544.02% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DNTH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -215.78% |
| Shareholder Yield | -215.78% |
| Earnings Yield | -17.77% |
| FCF Yield | -16.04% |
Analyst Forecast
The average price target for DNTH is $53.00, which is 200.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $53.00 |
| Price Target Difference | 200.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 99.37% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DNTH has an Altman Z-Score of 21.13 and a Piotroski F-Score of 2.
| Altman Z-Score | 21.13 |
| Piotroski F-Score | 2 |